fda warning letters compounding semaglutide september 2025 Issues to Telehealth Companies for False Clai FDA to Restrict Ingredients Used

(2005) Characterization of glucagon-like peptide-1 receptor beta-arrestin 2 interaction: a high-affinity receptor phenotype

In a large 2-year clinical trial involving 743 patients with a BMI of 2847, those taking orlistat (the active ingredient in Alli) lost, on average, 10.2% of their body weight during the first year, which is significantly more than the 6.1% lost by the placebo group. Patients who continued taking orlistat into the second year regained half as much weight as those who switched to placebo, demonstrating its effectiveness not only for weight loss but also for preventing weight regain. In addition to weight reduction, participants experienced improvements in cholesterol levels, glucose, and insulin concentrations. When used correctly alongside a balanced diet, Alli can be a powerful tool for achieving and maintaining weight loss

GIP:

Patients perspective of medication adherence in chronic conditions: a qualitative study

Managing diabetes during glucocorticoid therapy